Axsome Therapeutics reported third-quarter net product revenue of $259.7 million, a 52% increase from the prior-year period, driven by strong sales of Auvelity ($207.6 million) and Sunosi ($48.2 million). The company posted a net loss of $12.9 million, or $0.25 per share, compared to a $47.2 million loss in the same quarter last year. Axsome also announced that its SUMMIT Phase 3 trial for AXS-05 in smoking cessation has been initiated and confirmed that cash and equivalents stood at $313.9 million as of September 30, 2026. The company is a biopharmaceutical firm focused on developing treatments for central nervous system disorders.
